Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin at 91.5%
Gross margin was 91.5% in Q1 FY2026. On a trailing-twelve-month basis it was 97.7%, down 2.3 pp year over year.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 85.9%
- Year-over-year change
- -14.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.9% | -14.1pp |
| FY2024 | 2024-12-31 | 100.0% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Gross Margin vs competitors
How PRLD compares with its peers on the latest reported figures
- PRLD's LTM Mar 2026 gross margin of 97.7% is the 5th highest of the 9 companies compared; the peer median is 90.4%.
- Its year-over-year change of -2.3 pp is the 4th highest of 7, against a peer median of -34.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 144.9% | — | — | |
| LTM Mar 2026 | 99.8% | — | — | |
| LTM Mar 2026 | 99.3% | +6.7 pp | +8.5 pp | |
| LTM Mar 2026 | 98.3% | -1.7 pp | -7.0 pp | |
| LTM Mar 2026 | 97.7% | -2.3 pp | — | |
| LTM Mar 2026 | 82.6% | +610.6 pp | -6.4 pp | |
| FY2025 | 33.7% | -66.3 pp | -106.4 pp | |
| LTM Mar 2026 | 22.3% | -77.7 pp | -10.8 pp | |
| LTM Mar 2026 | -17996.6% | -16820.4 pp | +19.0 pp | |
EPRXEupraxia Pharmaceuticals Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding PRLD) | 90.4% | -34.0 pp | -6.7 pp | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.